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Abstract
Brain derived neurotrophic factor (BDNF) seems to be involved in regulation of synaptic plasticity and neurogenesis. BDNF
plasma and serum levels have been associated with depression, Alzheimer’s disease, and other psychiatric and
neurodegenerative disorders. In a community sample, drawn from the Baltimore Longitudinal Study of Aging (BLSA), we
examined whether BDNF plasma concentration was associated with rates of age-related change in cognitive performance
(n=429) and regional brain volume (n=59). Plasma BDNF levels, which were significantly higher in females (p,0.05), were
not associated with either concurrent cognitive performance or rates of age-related change in performance across cognitive
domains (p’s.0.05). Sex differences in the relationship between BDNF and the trajectories of regional brain volume changes
were observed for the whole brain and frontal white matter volumes (p,0.05), whereby lower plasma BDNF was associated
with steeper volume decline in females but not males. Together, our findings contribute to furthering the understanding of
the relationships between plasma BDNF, structural brain integrity and cognition. Potential mechanisms mediating these
relationships merit further investigation.
Citation: Driscoll I, Martin B, An Y, Maudsley S, Ferrucci L, et al. (2012) Plasma BDNF Is Associated with Age-Related White Matter Atrophy but Not with Cognitive
Function in Older, Non-Demented Adults. PLoS ONE 7(4): e35217. doi:10.1371/journal.pone.0035217
Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan
Received November 29, 2011; Accepted March 13, 2012; Published April 16, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This research was supported by the Intramural Research Program of the National Institute on Aging. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: driscoli@uwm.edu
Introduction
Alzheimer’s disease (AD) is a fatal neurodegenerative disorder
characterized by the progressive loss of both grey and white
matter, and cognitive impairment. Understanding pathogenic
mechanisms and identifying biological risks is imperative to the
discovery of biomarkers for differential diagnosis and treatment, as
well as pharmacological targets. Much effort has focused on the
role of neurotrophic factors, particularly brain-derived neuro-
trophic factor (BDNF), in both the pathogenesis and the disease
course of AD [1,2].
BDNF is expressed throughout the brain, especially in the
prefrontal cortex and the hippocampus [3]. Reduced BDNF levels
in various brain regions have been implicated in the pathogenesis
of neurodegenerative and psychiatric disorders [2]. Although
human findings derive primarily from investigations of an allelic
variant of BDNF (Val66Met), cumulative physiological, genetic and
neuroimaging findings all favor the idea that BDNF influences
cognitive function [4]. Moreover, Val66Met has been related to
smaller hippocampal volumes [3,5,6] , which in turn are
associated with worse memory [7] and more rapid conversion to
dementia [8]. The mechanisms underlying these BDNF associa-
tions with brain function and structure, however, remain unclear.
It is also unclear whether there is a relationship between BDNF
genotypes and BDNF measured in plasma.
There are only a limited number of studies examining the
relationships between polymorphisms in BDNF gene and plasma
BDNF. In rhesus monkeys, a Val to Met transition in the pro-
BDNF domain, similar to a well-described variant in the human
gene, seems to affect peripheral levels of BDNF [9]. However, in a
relatively large community sample of healthy adults (N=391)
drawn from the Baltimore Longitudinal Study of Aging BDNF
plasma levels were not associated with the Val66Met variant in
BDNF gene in either men or women [10]. The rs7124442T/
rs11030102C/rs11030119G haplotype in the BDNF gene was
associated with higher BDNF plasma levels, albeit in eating
disorder patients while a similar but non-significant trend was
observed in control group consisting of sibling pairs discordant for
the disorder [11].
It has become apparent that BDNF is present outside the
central nervous system (CNS) and circulates systemically. Despite
evidence from both human and non-human studies demonstrating
the role for BDNF in the regulation of energy metabolism and the
cardiovascular system [12,13], little is known about the role of
plasma BDNF in pathological states. The identification of
potential biomarkers that can be measured non-invasively in-vivo
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understanding of the role of these biomarkers in normal aging, and
as distinct from explicit disease or pathology, is a pre-requisite to
the development of rational approaches to prevention and
treatment. Limited existing literature suggests that low BDNF
levels in the cerebrospinal fluid (CSF) are associated with cognitive
decline, both cross-sectionally and longitudinal [14]; however,
little is known about the association of peripheral BDNF levels
with either brain structure or cognition in late life.
To elucidate the role for BDNF in structural and functional
brain integrity during aging, we measured plasma BDNF in a non-
clinical sample of older, community dwelling individuals who were
prospectively followed through the Baltimore Longitudinal Study
of Aging (BLSA). We hypothesized that lower levels of plasma
BDNF would be associated with both steeper regional brain
volume decline and decline in performance on cognitive tasks
dependent on those regions.
Results
Participant characteristics are summarized in Table 1. The age
range was from 50 to 97.5 years (56–90 for the neuroimaging (NI)
sub-sample). There were no significant differences in age,
education, race, follow-up interval or the number of assessments
between the whole sample and the NI subsample. Results are
reported as significant if p#0.05, although with Bonferroni
correction for multiple comparisons, results would be considered
significant at p#0.0013.
Plasma BDNF levels are greater in females compared to
males
BDNF plasma concentration in our sample averaged 759 pg/
ml (SD=551; range 38–2475). Older age was significantly
associated with lower plasma BDNF (F(1,325)=5.39, p=0.02).
Plasma BDNF levels were significantly higher in females (p,0.05)
than in males. There were no significant relationships between
plasma BDNF and race (p.0.8) or education (p.0.9).
Plasma BDNF does not predict cognitive performance
No significant relationships were observed between plasma
BDNF and neuropsychological test scores obtained at the same
visit as the blood sample (all p.0.1). Similarly, there were no
significant relationships between plasma BDNF and mean
cognitive scores on each test across all available visits (all
p.0.09). The lack of significant associations held when examining
males and females separately (p$0.05). Plasma BDNF levels did
not predict the rates of change with age in performance on any of
the cognitive domains examined (p’s.0.1).
Higher plasma BDNF levels are associated with slower
change in white matter volume with age (Table 2)
A significant BDNF by sex interaction was observed for the
trajectories of frontal WM volume (F(1,360)=7.52, p=0.006;
Table 1), where a strong but marginally significant trend was
present for slower rates of frontal WM decline in association with
higher BDNF levels in females (p=0.05). A marginally significant
trend was noted for slower rates of whole brain volume changes
with age in association with higher BDNF levels in females
(p=0.05). Cross-sectional analyses revealed a general lack of
relationship between any of the regional brain volumes examined
and plasma BDNF (p$0.05), except for occipital WM
(F(1,59.7)=7.47, p=0.008) where higher plasma BDNF was
associated with larger volumes in males (p=0.002).
Discussion
Our results are in accord with the existing literature reporting
lower serum and plasma BDNF levels with increasing age
[12,15,16], with significantly higher levels observed in women
compared to men [12,16–18]. We found that lower plasma BDNF
was associated with steeper rates of age-related regional brain
volume atrophy. Contrary to our expectations, however, we
observed no associations between circulating plasma BDNF levels
and either concurrent cognitive performance or the rate of change
in cognitive performance with age.
Human genetic studies implicate BDNF gene involvement in
cognitive function, specifically memory and executive function
[4,19]. Evidence also suggests that higher serum BDNF levels are
associated with better cognitive performance in healthy older
adults [15]. We found no associations between plasma BDNF
levels and either concurrent cognitive performance, mean
cognitive performance across all available assessments, or the rate
of change in cognition with age across domains in a large sample
of healthy, older individuals. The lack of associations between
plasma BDNF and cognitive performance in our sample stands in
contrast to the only existent study exploring this relationship in a
large Eastern Finnish sample (N=1389). In the Finnish sample,
the risk for worse performance on tests tapping memory and
general cognitive function increased with a drop in plasma BDNF,
but the associations were only present for women and not men
[17]. Li and colleagues [14] however, reported that lower CSF
BDNF concentration was associated with poorer immediate and
delayed recall measured at baseline and three years later. Given
the general lack of studies on this topic, discrepancies between our
findings and those of the two above-mentioned studies may reflect
methodological differences in general and more specifically,
differences in participant sampling. Cross-sectional studies of
normal individuals may be contaminated with individuals in
prodromal stages of impairment that goes unnoticed due to
inherent lack of prospective information. It is possible that plasma
Table 1. Sample Characteristics.
N Baseline Age Follow-up Interval
Number of
Assessments Plasma BDNF Education Race B/W
Sample 429 61.9 (9.1) 9.3 (4.5) 5.3 (3.2) 770 (570) 16.3 (2.6) 121/308
Males 216 63.1 (9.3) 9.5 (4.6) 5.4 (3.2) 647 (526) 16.5 (2.7) 47/169
Females 213 60.6 (8.9) 9.1 (8.9) 5.2 (3.2) 896 (586) 16.1 (2.5) 74/139
Mean (SD).
doi:10.1371/journal.pone.0035217.t001
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normal range of function in non-demented, healthy older adults,
whereby considerable decrease in BDNF may only be observable
in the late stage of cognitive decline or dementia, as is the case with
bipolar disorder for example [20].
We found that lower plasma BDNF is associated with steeper
regional brain volume decline. In our sample, lower BDNF levels
predicted steeper white matter atrophy and this relationship was
present in women but not men. The mechanisms underlying the
apparent sex differences in findings remain elusive, however,
ovarian steroids have been implicated as a modulating factor on
BDNF levels [21]. Effects of estrogen on brain BDNF have been
well documented in rodents [22,23], albeit mice used in these
studies were young.
Our findings differ from the existing literature, which reports
significant associations of gray matter and the hippocampus with
either serum BDNF [7] or Val66Met polymorphism [24,25]. Basic
research, however, suggests a role for BDNF in white matter
neuroprotection, whereby BDNF application promotes secondary
decrease of white matter lesion size even though it does not
prevent lesions from appearing [26]. Moreover, BDNF has been
implicated as an important factor associated with white matter
volume in patients with multiple sclerosis independent of BDNF
Val66Met (rs6265) genotype [27].
Our study is not without limitations. There is currently no
reliable method to detect both pro-BDNF and BDNF in human
plasma or serum, as there is antibody cross-reactivity between pro-
BDNF and BDNF due to their high sequence homology. Thus, at
this point in time, it is difficult to determine whether changes in
plasma or serum BDNF reflect pro-BDNF, BDNF or both. Novel
assays need to be developed that can accurately and quantitatively
distinguish between pro-BDNF and BDNF. Moreover, the present
sample is not population-based; participants are highly educated
and predominantly Caucasian. The relative homogeneity of the
sample, however, may be seen as an advantage because the
majority of our sample has good access to medical care and has
remained relatively healthy over the follow-up interval. Moreover,
average BDNF plasma values vary widely across studies, most
likely owing to the fact that the concentration of BDNF in plasma
is state-dependent [28–30]. Methodological differences notwith-
standing, the average BDNF plasma concentration in our study is
similar to that of other non-clinical samples [16,17]. These
limitations, however, should not undermine the unique aspects of
our study, namely a large number of elderly individuals who were
prospectively followed for many years on an annual basis,
extensively characterized, and studied with state-of-the art image
processing methods. Moreover, we characterize age-related
changes in many of the regional brain volumes that have not
been previously investigated in relation to plasma BDNF.
Another issue in interpreting our results is the analysis of a
number of cognitive domains and a number of brain volume
measurements without adjustment for multiple comparisons.
Given the relative dearth of studies investigating associations
between plasma BDNF and cognitive and brain outcomes, our
exploratory investigation in a well-characterized longitudinal
sample should provide directions for future research. In addition,
our long follow-up interval ensures great power for detecting even
Table 2. Cross-sectional (main) effects of BDNF on regional brain volume and longitudinal brain volume changes (annual rates in
cm
3) in relation to plasma BDNF.
Cross-sectional Effects Longitudinal Effects
REGION BDNF Sex* BDNF BDNF* interval Sex*BDNF *interval
Whole Brain 0.77 (1.28) 0.46 (2.61) 0.06 (0.05) 20.22 * (0.11)
vCSF 0.03 (0.34) 0.66 (0.70) 0.35 0.014 (0.01) 0.04 (0.03)
GM 20.54 (0.74) 22.68 (1.52) 20.044 (0.05) 20.12 (0.09)
WM 1.21 (0.89) 3.03 (1.82) 0.07 (0.04) 20.033 (0.09)
Gray Matter:
Frontal 20.10 (0.25) 20.79 (0.52) 20.02 (0.02) 20.04 (0.03)
Temporal 20.17 (0.18) 20.56 (0.37) 20.02 (0.02) 20.01 (0.03)
Parietal 20.26 (0.16) 20.57 (0.34) 20.01 (0.01) 0.0004 (0.02)
Occipital 20.08 (0.13) 20.16 (0.27) 0.003 (0.01) 20.013 (0.02)
White Matter:
Frontal 0.58 (0.39) 0.80 (0.79) 0.001 (0.02) 20.09 ** (0.03)
Temporal 0.20 (0.23) 0.49 (0.48) 0.04 ** (0.01) 20.01 (0.03)
Parietal 0.18 (0.19) 0.69 (0.39) 0.02 (0.01) 0.02 (0.02)
Occipital 0.26* (0.12) 0.71 ** (0.25) 0.02 (0.01) 20.01 (0.02)
Other Regions:
Orbito-frontal 20.03 (0.06) 20.07 (0.11) 20.002 (0.004) 20.01 (0.01)
Hippocampus 20.004 (0.01) 20.012 (0.03) 0.001 (0.001) 0.002 (0.002)
Cingulate Gyrus 20.02 (0.06) 20.02 (0.13) 20.003 (0.01) 0.01 (0.01)
Precuneus 20.003 (0.02) 20.05 (0.04) 0.001 (0.001) 20.003 (0.002)
Results are expressed as b-coefficients (S.E.).
**p,0.01.
*p,0.05.
doi:10.1371/journal.pone.0035217.t002
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sectional design.
To our knowledge, this study is the first longitudinal study
exploring associations between plasma BDNF levels, brain volume
and cognitive function in healthy older individuals. Overall, our
results suggest a role for BDNF in structural brain integrity, but no
direct associations with cognitive function or change in cognition
with age. Together, our findings from the BLSA cohort contribute
to furthering the understanding of the relationships between
plasma BDNF concentration, brain volume integrity and cognitive
function with age. Further research is needed in order to
understand not only the role for BDNF in brain structure and
function, but also the relationship between peripheral BDNF (both
plasma and serum) and its genetic variants. Additional research is
needed to demonstrate the mechanisms underlying the relation-
ship between plasma BDNF and brain volume integrity, as well as
the sex differences that might be moderating the relationship,
especially considering that current knowledge is primarily based
on animal studies and human genetic studies.
Materials and Methods
Participants
The sample was drawn from the BLSA [31], an ongoing
multidisciplinary study of community-dwelling volunteers. At each
evaluation, participants underwent neuropsychological testing, a
neurological exam, interval medical history, medication review,
and a structured informant and subject interview detailed
elsewhere [31,32]. Inclusion criteria are good general health.
Specific exclusionary criteria at enrollment for the BLSA NI sub-
study included a history of CNS disease (dementia, stroke,
Parkinson’s disease, epilepsy, and other neurological conditions),
severe cardiac disease (including myocardial infarction, coronary
bypass surgery, or angioplasty), and metastatic cancer. All
individuals who went on to develop cognitive impairment or
dementia, based on standardized consensus diagnostic procedures
for the BLSA [33] using Peterson criteria for MCI [34], were
excluded from analyses. BLSA studies were approved by the local
institutional review boards of both the National Institute on Aging
and Johns Hopkins Medical Institutions, and all participants gave
written informed consent prior to each assessment.
Blood samples were obtained from 429 participants (213 F/216
M; 64% Caucasian) during regularly scheduled visits from January
2007 to June 2008. Participants ranged in age from 50 to 98 years
(M=62, SD=9.1 and were on average college-educated
(M=16.3 years of education, SD=2.6). A subset of 59
participants, who were characteristically similar to the larger
BLSA sample, also underwent prospective, annual neuroimaging
(NI) assessments for up to 10 years. Sample characteristics are
summarized in Table 1.
Measurement of plasma BDNF concentration
Blood samples were obtained in the morning after an overnight
fast. Blood samples were centrifuged at 3000 rpm for 30 minutes
at 4uC. Plasma was carefully collected and was snap frozen on dry
ice and subsequently stored at 280uC, until used for further
analyses. BDNF plasma levels were measured using a commer-
cially available ELISA kit (Promega, Madison, WI; sensitivity
range 7.8–500 pg/ml; inter-assay variation=8.8% (low concen-
tration), 2.9% (medium concentration), and 2.2% (high concen-
tration) as described in more detail previously [35–37]. Briefly, the
plasma samples were diluted 1:5 in block and sample buffer
provided by the kit. The BDNF plate was coated with primary
BDNF antibody overnight, the following day block and sample
buffer were added to each well for 1 hour, and subsequently the
standards and samples were added for 2 hours. Thereafter, anti-
human BDNF pAb secondary antibody was added for 2 hours and
the anti-Ig Y HRP conjugate was added for 1 hour. Then, TMB
One solution was added to each well for 5 minutes and the
reaction was stopped with hydrochloric acid. The plate was
analyzed within 30 minutes at 450 nm.
Neuropsychological assessment
Assessments spanned five different cognitive domains: memory,
word knowledge, attention, executive function, and visuo-spatial
abilities across a battery of 12 neuropsychological tests. Memory
was assessed using the California Verbal Learning Test (CVLT)
[38], Benton Visual Retention Test (BVRT) [39] and Cued
Selective Reminding Test (CSR) [40]. Primary Mental Abilities
Vocabulary (PMA) [41] assessed word knowledge. Verbal fluency
was assessed by letter fluency (FAS) and semantic fluency [42].
The Digit Span subtest from the Wechsler Adult Intelligence
Scale-Revised [43] and the Trail Making Test [44], parts A and B,
assessed attention and executive function. Digits Forward and
Trails A assessed attention. Digits Backward, Trails B, and Verbal
Fluency (categories and letters) measured executive function. The
Card Rotations Test [45] assessed visuo-spatial function.
MRI acquisition
Scanning was performed on a GE Signa 1.5 Tesla scanner
(Milwaukee, WI) using a high-resolution volumetric spoiled-grass
(SPGR) axial series (TR=35 ms, TE=5 ms, FOV=24 cm, flip
angle=45u, matrix=2566256, NEX=1, voxel dimensions
0.9460.9461.5 mm).
MRI image analysis
Image processing procedures have been previously described
and validated [46–48]. Briefly, images were corrected for head tilt
and rotation, and reformatted parallel to the anterior-posterior
commissure plane. Extracranial tissue was removed using a semi-
automated procedure followed by manual editing. Next, images
were segmented into white matter (WM), gray matter (GM), and
cerebrospinal fluid (CSF). The final step involved stereotaxic
normalization and tissue quantitation for specific regions of
interest. A template-based deformation approach was employed,
using the ICBM standard MRI (Montreal Neurologic Institute) as
the template and a hierarchical elastic matching algorithm for
deformation and regions of interest determination [49]. All images
were normalized individually to the same template. Voxel-based
analysis utilized the RAVENS approach [47]. Intracranial volume
(ICV) is determined using the template warping algorithm
modified for head image registration. First, the ICV in the
template is manually and carefully delineated by an expert. Then,
the template with its ICV mask is warped to the space of each
individual head. Finally, the warped ICV mask of the template is
used to directly extract the ICV of the individual.
Statistical analysis
Linear mixed effects models (i.e., random effects models) [50,51]
were performed using SAS 9.1 (SAS Institute Inc.; Cary, NC) to
investigate the associations between BDNF and cross-sectional and
longitudinal measures of cognitive function and regional brain
volume changes. Pair-wise multiple comparisons with Tukey
adjustments were carried out to compare sample characteristics.
Regional brain volumes and performance on individual
neuropsychological tests served as dependent variables. For
analysis of BDNF in relation to cognitive change, the fixed effects
Plasma BDNF, MRI, Cognition
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35217included the following terms: intercept, sex, age at the last
measurement (agelast), BDNF, interval (from last MRI),
sex*BDNF, sex*interval, agelast*interval, BDNF*interval and
sex*BDNF*interval. Regional brain volume analyses followed
the same model, but included intra-cranial volume as an
additional covariate.
We used effect coding for sex (20.5 for female and 0.5 for
male). BDNF was centered at the sample mean and divided by
100. Age at the last measurement was centered at 75. This model
formulation allowed us to investigate cross-sectional (concurrent)
BDNF effects on brain volumes and cognitive measures and
BDNF effects on the longitudinal rates of change in brain volume
and cognition simultaneously after adjusting for age and sex.
Model reductions were conducted on random effects, which
included intercept and interval. Non-significant random effects
were dropped from the model. No model reductions were
performed on the fixed effects [52].
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